IE49073B1 - Antihypertensive pharmaceutical compositions - Google Patents
Antihypertensive pharmaceutical compositionsInfo
- Publication number
- IE49073B1 IE49073B1 IE336/80A IE33680A IE49073B1 IE 49073 B1 IE49073 B1 IE 49073B1 IE 336/80 A IE336/80 A IE 336/80A IE 33680 A IE33680 A IE 33680A IE 49073 B1 IE49073 B1 IE 49073B1
- Authority
- IE
- Ireland
- Prior art keywords
- composition according
- active agents
- active agent
- endralazine
- salidiuretic
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
- 230000003276 anti-hypertensive effect Effects 0.000 title claims description 3
- 206010020772 Hypertension Diseases 0.000 claims abstract description 16
- ALAXZYHFVBSJKZ-UHFFFAOYSA-N endralazine Chemical compound C1CC=2N=NC(NN)=CC=2CN1C(=O)C1=CC=CC=C1 ALAXZYHFVBSJKZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 230000000054 salidiuretic effect Effects 0.000 claims abstract description 16
- 229960002029 endralazine Drugs 0.000 claims abstract description 15
- 229960002508 pindolol Drugs 0.000 claims abstract description 11
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims abstract description 10
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960002817 metolazone Drugs 0.000 claims abstract description 8
- 229960002003 hydrochlorothiazide Drugs 0.000 claims abstract description 7
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000013543 active substance Substances 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 22
- LBXHRAWDUMTPSE-AOOOYVTPSA-N 4-chloro-N-[(2S,6R)-2,6-dimethyl-1-piperidinyl]-3-sulfamoylbenzamide Chemical compound C[C@H]1CCC[C@@H](C)N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 LBXHRAWDUMTPSE-AOOOYVTPSA-N 0.000 claims description 14
- 229960004070 clopamide Drugs 0.000 claims description 14
- 239000012730 sustained-release form Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008247 solid mixture Substances 0.000 claims 1
- SSEAPVMQZPKNQZ-UHFFFAOYSA-N 2-(aminomethyl)-4-tert-butyl-6-iodophenol Chemical compound CC(C)(C)C1=CC(I)=C(O)C(CN)=C1 SSEAPVMQZPKNQZ-UHFFFAOYSA-N 0.000 abstract description 3
- 229960002155 chlorothiazide Drugs 0.000 abstract description 3
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 abstract description 2
- ZUNJWRJEKCRIMZ-UHFFFAOYSA-N 3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CSCC1=CC=CC=C1 ZUNJWRJEKCRIMZ-UHFFFAOYSA-N 0.000 abstract description 2
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 abstract description 2
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 abstract description 2
- 229960003515 bendroflumethiazide Drugs 0.000 abstract description 2
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 abstract description 2
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 abstract description 2
- 229960001541 benzthiazide Drugs 0.000 abstract description 2
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 abstract description 2
- 229960004064 bumetanide Drugs 0.000 abstract description 2
- 229960001523 chlortalidone Drugs 0.000 abstract description 2
- 229960003176 cyclothiazide Drugs 0.000 abstract description 2
- BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 abstract description 2
- 229960003199 etacrynic acid Drugs 0.000 abstract description 2
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 abstract description 2
- 229960003883 furosemide Drugs 0.000 abstract description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 abstract description 2
- 229960003313 hydroflumethiazide Drugs 0.000 abstract description 2
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 abstract description 2
- 229960003739 methyclothiazide Drugs 0.000 abstract description 2
- 229960005483 polythiazide Drugs 0.000 abstract description 2
- 229920000046 polythiazide Polymers 0.000 abstract description 2
- 229960000356 tienilic acid Drugs 0.000 abstract description 2
- AGHANLSBXUWXTB-UHFFFAOYSA-N tienilic acid Chemical compound ClC1=C(Cl)C(OCC(=O)O)=CC=C1C(=O)C1=CC=CS1 AGHANLSBXUWXTB-UHFFFAOYSA-N 0.000 abstract description 2
- 229960004813 trichlormethiazide Drugs 0.000 abstract description 2
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 abstract description 2
- -1 dopamide Chemical compound 0.000 abstract 1
- 229960000577 quinethazone Drugs 0.000 abstract 1
- AGMMTXLNIQSRCG-UHFFFAOYSA-N quinethazone Chemical compound NS(=O)(=O)C1=C(Cl)C=C2NC(CC)NC(=O)C2=C1 AGMMTXLNIQSRCG-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 10
- 239000012458 free base Substances 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 10
- 239000003826 tablet Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 230000001631 hypertensive effect Effects 0.000 description 4
- 150000003839 salts Chemical group 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH178579A CH643457A5 (de) | 1979-02-22 | 1979-02-22 | Pharmazeutische praeparate zur behandlung der hypertonie. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE800336L IE800336L (en) | 1980-08-22 |
| IE49073B1 true IE49073B1 (en) | 1985-07-24 |
Family
ID=4218544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE336/80A IE49073B1 (en) | 1979-02-22 | 1980-02-20 | Antihypertensive pharmaceutical compositions |
Country Status (20)
| Country | Link |
|---|---|
| JP (1) | JPS55115823A (it) |
| AT (1) | AT378915B (it) |
| AU (1) | AU538599B2 (it) |
| BE (1) | BE881763A (it) |
| CA (1) | CA1147657A (it) |
| CH (1) | CH643457A5 (it) |
| DE (1) | DE3005029C2 (it) |
| FR (1) | FR2449450A1 (it) |
| GB (1) | GB2044101B (it) |
| HU (1) | HU187271B (it) |
| IE (1) | IE49073B1 (it) |
| IL (1) | IL59432A (it) |
| IT (1) | IT1145433B (it) |
| MY (1) | MY8500619A (it) |
| NL (1) | NL8001000A (it) |
| NZ (1) | NZ192924A (it) |
| PH (1) | PH17118A (it) |
| PT (1) | PT70855A (it) |
| SE (2) | SE8001121L (it) |
| ZA (1) | ZA801018B (it) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2537434A1 (fr) * | 1982-12-09 | 1984-06-15 | Sandoz Sa | Composition pharmaceutique d'endralazine sous forme retard |
| GB2367242B (en) * | 2000-09-21 | 2004-07-28 | Henderson Morley Res & Dev Ltd | Antiviral treatment |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2458155A1 (de) * | 1973-12-19 | 1975-07-03 | Sandoz Ag | Neue pharmazeutische praeparate |
-
1979
- 1979-02-22 CH CH178579A patent/CH643457A5/de not_active IP Right Cessation
-
1980
- 1980-02-11 DE DE3005029A patent/DE3005029C2/de not_active Expired
- 1980-02-13 SE SE8001121A patent/SE8001121L/ not_active Application Discontinuation
- 1980-02-15 GB GB8005245A patent/GB2044101B/en not_active Expired
- 1980-02-18 BE BE1/9727A patent/BE881763A/fr not_active IP Right Cessation
- 1980-02-19 NL NL8001000A patent/NL8001000A/nl not_active Application Discontinuation
- 1980-02-20 CA CA000346083A patent/CA1147657A/en not_active Expired
- 1980-02-20 PT PT70855A patent/PT70855A/pt unknown
- 1980-02-20 NZ NZ192924A patent/NZ192924A/en unknown
- 1980-02-20 AU AU55742/80A patent/AU538599B2/en not_active Ceased
- 1980-02-20 IT IT47950/80A patent/IT1145433B/it active
- 1980-02-20 IL IL59432A patent/IL59432A/xx unknown
- 1980-02-20 IE IE336/80A patent/IE49073B1/en unknown
- 1980-02-20 FR FR8003669A patent/FR2449450A1/fr active Granted
- 1980-02-21 JP JP1980480A patent/JPS55115823A/ja active Pending
- 1980-02-21 AT AT0095580A patent/AT378915B/de not_active IP Right Cessation
- 1980-02-21 PH PH23672A patent/PH17118A/en unknown
- 1980-02-21 HU HU80402A patent/HU187271B/hu unknown
- 1980-02-22 ZA ZA00801018A patent/ZA801018B/xx unknown
-
1982
- 1982-04-15 SE SE8202357A patent/SE8202357L/xx not_active Application Discontinuation
-
1985
- 1985-12-30 MY MY619/85A patent/MY8500619A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL59432A (en) | 1984-08-31 |
| FR2449450B1 (it) | 1983-07-22 |
| GB2044101B (en) | 1983-09-07 |
| AU5574280A (en) | 1980-08-28 |
| NL8001000A (nl) | 1980-08-26 |
| JPS55115823A (en) | 1980-09-06 |
| IT8047950A0 (it) | 1980-02-20 |
| DE3005029C2 (de) | 1987-02-12 |
| PH17118A (en) | 1984-06-01 |
| ZA801018B (en) | 1981-09-30 |
| IT1145433B (it) | 1986-11-05 |
| HU187271B (en) | 1985-12-28 |
| DE3005029A1 (de) | 1980-09-04 |
| BE881763A (fr) | 1980-08-18 |
| CA1147657A (en) | 1983-06-07 |
| GB2044101A (en) | 1980-10-15 |
| IE800336L (en) | 1980-08-22 |
| PT70855A (fr) | 1980-03-01 |
| NZ192924A (en) | 1984-05-31 |
| SE8202357L (en) | 1982-04-15 |
| SE8001121L (sv) | 1980-08-23 |
| FR2449450A1 (fr) | 1980-09-19 |
| IL59432A0 (en) | 1980-05-30 |
| CH643457A5 (de) | 1984-06-15 |
| AU538599B2 (en) | 1984-08-23 |
| AT378915B (de) | 1985-10-25 |
| MY8500619A (en) | 1985-12-31 |
| ATA95580A (de) | 1985-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0305051B1 (en) | Orally sustained-release acetaminophen formulation and process to obtain it | |
| RU2298418C2 (ru) | Комбинация по меньшей мере двух соединений, выбранных из групп антагонистов at1-рецептора или ингибиторов асе (ангиотензинпревращающий фермент), или ингибиторов hmg-coa-редуктазы (бета-гидрокси-бета-метилглутарил-кофермент-а-редуктаза) | |
| US6162802A (en) | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor | |
| AU703242B2 (en) | Film coated tablet of paracetamol and domperidone | |
| JP2004519440A (ja) | アムロジピンとベナゼプリル／ベナゼプリラートの治療上の組み合せ | |
| EA014707B1 (ru) | Новая форма введения рацекадотрила | |
| US6544554B1 (en) | Regulated release preparations | |
| EP0408273B1 (en) | Fosinopril tablet formulations | |
| CZ147494A3 (en) | Pharmaceutical preparation and process for preparing thereof | |
| US5047235A (en) | Pharmaceutical preparations having an antihypertensive and cardioprotective effect | |
| US20080008751A1 (en) | Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof | |
| RU2182002C2 (ru) | Композиция с фиксированной дозой ингибитора ангиотензин-превращающего фермента и антагониста кальциевых каналов, способ ее изготовления и применение для лечения сердечно-сосудистых заболеваний | |
| IE49073B1 (en) | Antihypertensive pharmaceutical compositions | |
| AU756338B2 (en) | Stabile compositions comprising levosimendan and alginic acid | |
| WO1999018957A1 (en) | Stable pharmaceutical composition containing amlodipine besylate and atenolol | |
| CA1059912A (en) | Antidepressant compound | |
| NO329495B1 (no) | Galeniske former for oral administrasjon med forlenget frigjoring av molsidomin | |
| NZ199783A (en) | Sustained release compositions containing endralazine embedded in a wax matrix | |
| JPH05229944A (ja) | モノアミノオキシダーゼｂ阻害因子 | |
| IE43955B1 (en) | Pharmaceutical composition and dosage units thereof | |
| RU2203052C1 (ru) | Твердая лекарственная форма эналаприла | |
| EP1889629A1 (en) | Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof | |
| IE43611B1 (en) | Antihypertonic agent | |
| CA2659814A1 (en) | Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof | |
| FR2537434A1 (fr) | Composition pharmaceutique d'endralazine sous forme retard |